IN8bio presents updated data from Phase 1 trial of INB-100 at EHA

IN8bio cell therapies presents updated data from its Phase 1 trial of INB-100 at the European Hematology Association EHA 2024 Hybrid Congress. The data from INB-100 demonstrated that 100% of evaluable leukemia patients remained alive, progression-free, and in durable CR through one year as of May 31. Historically, published data demonstrated that up to ~50% of patients with hematologic malignancies undergoing HSCT with reduced intensity conditioning elapse by one year and often succumb to the disease shortly thereafter. Two of the patients treated with INB-100 remain alive and relapse free for over three and a half years, and a third patient is now nearing three years. Furthermore, INB-100 has demonstrated for the first time, the in vivo expansion and persistence of a haplo-matched allogeneic, or donor-derived, cellular therapy at 365 days, with blood levels of gamma-delta T cells surpassing levels previously associated with greater survival.”These data demonstrate the potential of allogeneic INB-100 gamma-delta T cells to provide durable relapse-free periods for patients with high-risk or relapsed AML and other hematologic malignancies undergoing HSCT,” said Trishna Goswami, MD, Chief Medical Officer of IN8bio.